# US 2019/0317087 A1 · Novel assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0317087 A1
- Document ID: US20190317087A1
- Status: Published application
- Kind: A1
- Application number: 16/418,272
- Filed: 2019-05-21
- Published: 2019-10-17
- Earliest claimed: 2013-04-05
- Assignees: Idl Biotech AB
- Applicants: Idl Biotech AB
- Inventors: Yiva D'AMICO; Gunnar Magnusson
- Web page: https://patentgrep.com/patent/US20190317087A1

## CPC

- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/57595: {involving intracellular compounds}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/4742: Keratin; Cytokeratin
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method is described for the detection of at least two of cytokeratins 8, 18 and 19 in a sample. It is practiced by contacting the sample with a solid phase having a first antibody with specificity for cytokeratin 8, a second antibody with specificity for cytokeratin 18 and, optionally, a third antibody with specificity for a first epitope of cytokeratin 19 bound to it and allowing cytokeratins in the sample to bind to the bound antibodies to form complexes. The complexes are then contacted with a first labelled antibody with specificity for a dimer of cytokeratin 8 and 18 and optionally a second labelled antibody with specificity for a second epitope of cytokeratin 19 and allowing the labelled antibodies to bind to the complexes. The labelled antibodies bound to the complexes are then detected. A method for quantitative determination of soluble fragments of at least two of cytokeratin 8, 18 and 19 in a sample and a kit are also described.

## Claims

### Claim 1

A method for detecting soluble fragments of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19 in a fluid sample of a human subject, comprising the steps of contacting said fluid sample with a solid phase having immobilized thereon a first antibody having specificity for cytokeratin 8, a second antibody having specificity for cytokeratin 18 and optionally a third antibody having specificity for a first epitope of cytokeratin 19;
allowing soluble fragments of cytokeratins to bind to said first, second and optionally third antibodies thereby forming complexes;
contacting said complexes with a first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and optionally a second labelled antibody having specificity for a second epitope of cytokeratin 19;
allowing said labelled antibodies to bind to said complexes; and
detecting said labelled antibodies bound to said complexes.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said antibodies are monoclonal antibodies.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said first labelled antibody has specificity for the α-helix 2B 2 (aa 414-429 as set forth in SEQ ID NO:1) of cytokeratin 18, and, if present, said second labelled antibody has specificity for the α-helix 2B 2 (aa 311-335 as set forth in SEQ ID NO:2) of cytokeratin 19.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The method according to claim 3, wherein said first labelled antibody is M21, and, if present, said second labelled antibody is A53-B/A2.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein said first immobilized antibody has specificity for the α-helix 2B (aa 340-365 as set forth in SEQ ID NO:3), said second immobilized antibody has specificity for the α-helix 2B (aa 320-350 as set forth in SEQ ID NO:4), and, if present, said third immobilized antibody has specificity for the α-helix 2B (aa 340-370 as set forth in SEQ ID NO:5).

### Claim 8 (depends on 7)

The method according to claim 7, wherein said first immobilized antibody is 6D7, said second immobilized antibody is 3F3, and, if present, said third immobilized antibody is IDLC4.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said first antibody having specificity for cytokeratin 8 constitutes 20-40% of total immobilized antibody, said second antibody having specificity for cytokeratin 18, constitutes 5-15% of total immobilized antibody, and said third antibody having specificity for cytokeratin 19 constitutes 50-70% of total immobilized antibody.

### Claim 10 (depends on 9)

The method according to claim 9, wherein said first antibody having specificity for cytokeratin 8 constitutes 30% of total immobilized antibody, said second antibody having specificity for cytokeratin 18, constitutes 10% of total immobilized antibody, and said third antibody having specificity for cytokeratin 19 constitutes 60% of total immobilized antibody.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the soluble fragments of cytokeratin 8 and 18 in the fluid sample are detected by a method comprising the steps of:
contacting said fluid sample with a solid phase having immobilized thereon a first antibody having specificity for cytokeratin 8, and a second antibody having specificity for cytokeratin 18;
allowing soluble fragments of cytokeratins in said sample to bind to said first and second antibodies thereby forming complexes;
contacting said complexes with a first labelled antibody having specificity for a dimer of cytokeratin 8 and 18;
allowing said labelled antibodies to bind to said complexes; and
detecting said labelled antibody bound to said complexes.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said labelled antibodies are labelled with horse radish peroxidase and detection is performed by adding a substrate capable of being converted to a detectable substance by said horse radish peroxidase.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said substrate is converted to a chromogenic substance by said horse radish peroxidase.

### Claim 14 (depends on 13)

The method according to claim 13, wherein said substrate is TMB (3,3′,5,5′-Tetramethylbenzidine).

### Claim 15 (depends on 1)

The method for quantitative determination of soluble fragments of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19 in a fluid sample of a human subject, comprising the method according to claim 1, and further comprising the step of:
quantitatively correlating the amount of bound first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and, if present, second labelled antibody having specificity for cytokeratin 19 with known amounts of soluble fragments of cytokeratins 8, 18 and/or 19.

### Claim 16 (depends on 11)

The method for quantitative determination of soluble fragments of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19 in a fluid sample of a human subject, comprising the method according to claim 11, and further comprising the step of:
quantitatively correlating the amount of bound first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and, if present, second labelled antibody having specificity for cytokeratin 19 with known amounts of soluble fragments of cytokeratins 8, 18 and/or 19.

### Claim 17

A method for detecting at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19 and soluble fragments thereof in a fluid sample of a human subject, comprising the steps of
contacting said fluid sample with a solid phase having immobilized thereon a first antibody having specificity for cytokeratin 8, a second antibody having specificity for cytokeratin 18 and optionally a third antibody having specificity for a first epitope of cytokeratin 19;
allowing cytokeratins and soluble fragments thereof to bind to said first, second and optionally third antibodies thereby forming complexes;
contacting said complexes with a first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and optionally a second labelled antibody having specificity for a second epitope of cytokeratin 19;
allowing said labelled antibodies to bind to said complexes; and
detecting said labelled antibodies bound to said complexes.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said antibodies are monoclonal antibodies.

### Claim 19 (depends on 17)

The method according to claim 17, wherein said first labelled antibody has specificity for the α-helix 2B 2 (aa 414-429 as set forth in SEQ ID NO:1) of cytokeratin 18, and, if present, said second labelled antibody has specificity for the α-helix 2B 2 (aa 311-335 as set forth in SEQ ID NO:2) of cytokeratin 19.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said first labelled antibody is M21, and, if present, said second labelled antibody is A53-B/A2.

### Claim 21 (depends on 17)

The method according to claim 17, wherein said first immobilized antibody has specificity for the α-helix 2B (aa 340-365 as set forth in SEQ ID NO:3), said second immobilized antibody has specificity for the α-helix 2B (aa 320-350 as set forth in SEQ ID NO:4), and, if present, said third immobilized antibody has specificity for the α-helix 2B (aa 340-370 as set forth in SEQ ID NO:5).

### Claim 22 (depends on 21)

The method according to claim 21, wherein said first immobilized antibody is 6D7, said second immobilized antibody is 3F3, and, if present, said third immobilized antibody is IDLC4.

### Claim 23 (depends on 17)

The method according to claim 17, wherein said first antibody having specificity for cytokeratin 8 constitutes 20-40% of total immobilized antibody, said second antibody having specificity for cytokeratin 18, constitutes 5-15% of total immobilized antibody, and said third antibody having specificity for cytokeratin 19 constitutes 50-70% of total immobilized antibody.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said first antibody having specificity for cytokeratin 8 constitutes 30% of total immobilized antibody, said second antibody having specificity for cytokeratin 18, constitutes 10% of total immobilized antibody, and said third antibody having specificity for cytokeratin 19 constitutes 60% of total immobilized antibody.

### Claim 25 (depends on 17)

The method according to claim 17, wherein the cytokeratin 8 and 18 and soluble fragments thereof in the fluid sample are detected by a method comprising the steps of:
contacting said fluid sample with a solid phase having immobilized thereon a first antibody having specificity for cytokeratin 8, and a second antibody having specificity for cytokeratin 18;
allowing cytokeratins 8 and 18 and soluble fragments thereof in said sample to bind to said first and second antibodies thereby forming complexes;
contacting said complexes with a first labelled antibody having specificity for a dimer of cytokeratin 8 and 18;
allowing said labelled antibodies to bind to said complexes; and
detecting said labelled antibody bound to said complexes.

### Claim 26 (depends on 17)

The method according to claim 17, wherein said labelled antibodies are labelled with horse radish peroxidase and detection is performed by adding a substrate capable of being converted to a detectable substance by said horse radish peroxidase.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said substrate is converted to a chromogenic substance by said horse radish peroxidase.

### Claim 28 (depends on 27)

The method according to claim 27, wherein said substrate is TMB (3,3′,5,5′-Tetramethylbenzidine).

### Claim 29 (depends on 17)

A method for quantitative determination of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19 and soluble fragments thereof in a fluid sample of a human subject, comprising the method according to claim 17, and further comprising the step of:
quantitatively correlating the amount of bound first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and, if present, second labelled antibody having specificity for cytokeratin 19 with known amounts of soluble fragments of cytokeratins 8, 18 and/or 19.

### Claim 30 (depends on 25)

A method for quantitative determination of at least two cytokeratins selected from the group consisting of cytokeratin 8, 18 and 19 and soluble fragments thereof in a fluid sample of a human subject, comprising the method according to claim 25, and further comprising the step of:
quantitatively correlating the amount of bound first labelled antibody having specificity for a dimer of cytokeratin 8 and 18 and, if present, second labelled antibody having specificity for cytokeratin 19 with known amounts of soluble fragments of cytokeratins 8, 18 and/or 19.
